Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, HTG, Randox

Premium
Affymetrix last week launched its 3' IVT Express Kit, which it claims is a faster and more reliable option for manual target preparation on Affymetrix' industry-standard 3' IVT array cartridges.
 
The kit offers streamlined protocols and requires less starting sample material, enabling researchers to generate high-quality gene expression results faster than previously, Affy said.
 
For example, the 3' IVT Express Kit requires 50 nanograms per sample, up to 20 times less than the previous One Cycle Kit. Another benefit is that assays can be run in just one day with 500 nanograms of starting material input versus two days with the One Cycle Kit. This allows assays to be completed overnight, Affy said.
 

 
HTG last week launched M3 Series, a multiplexed mini-microarray set up for biomarker discovery and gene profiling. The M3 series allows researchers to monitor the behavior of multiple genes in the same sample, simplifying experiments and lowering costs, HTG said.
 
According to HTG, the M3 Series consists of HTG's qCustom ArrayPlate, qFix Arrays, and two chemiluminescent imagers, the Omix II Imager, and Capella Imager, that are used in conjunction with the firm’s customizable multiplexed mini-microarrays.
 
In addition to the custom M3 arrays, HTG has also introduced qSelect Custom Arrays, built from an expanding library of on-demand genes.
 

 
Randox recently launched RanplexCRC, a diagnostic that can detect 28 mutations from four key genes in cancer or pre-cancer cells shed into the bowel. Selected mutations present in APC, KRAS, BRAF and Tp53, along with wild-type control sequences, are represented on two biochips, the company said.
 
The biochips are configured to work with Randox’s Evidence platform, an automated system for high-throughput laboratories, as well as its Evidence Investigator, a semi-automated system for low-throughput laboratories and research purposes.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.